Pro Medicus Limited (ASX:PME) shares storm to an all-time high on bumper profit growth

In early trade the Pro Medicus Limited (ASX: PME) share price pushed 4.5% higher to an all-time high of $9.09 following the release of the imaging IT provider’s full year results.

For the 12 months ended June 30 2018, Pro Medicus posted a 13.9% increase in revenue to $36 million and a 36.7% jump in profit after tax to $12.7 million. Underlying profit, excluding currency movements, was up 27.4% to $12.6 million.

As shown below, the main driver of this growth was the positive performance of its North American and European operations. Revenue in these segments increased 18.4% and 33.2%, respectively, in FY 2018. This made up for a soft performance from its Australian operation.

Source: Company presentation

The North American segment was given a boost from the signing of three key contracts. This included an A$18 million, seven-year contract with Yale New Haven Health, one of the leading academic institutions and a A$15 million, seven-year contract with Mercy Health for Visage Open Archive.

Pro Medicus’ strong bottom line growth was largely down to its North American business. CEO Sam Hupert stated that: “The key driver for margin and revenue growth was our North American business. We brought more sites online so had a good year in terms of professional services, which includes implementation and training. Those sites that were online continued to build their transaction volumes which is pretty much what we expected, so we’re very pleased with that.”

Before adding that: “Looking at margins, we’ve always said that the US is a higher margin business and therefore the greater the contribution from the US the higher the margins in total. As we grow this business and build our base of recurring transaction revenues in that market we should see further margin expansion.”

This ultimately led to earnings per share of 12.2 cents, up from 9 cents per share in FY 2017. And with the company remaining debt-free and seeing its cash reserves rise 10.8% to $25.2 million, the board was able to increase its full-year dividend by 50% to a fully franked 6 cents per share.

Should you invest?

As I mentioned yesterday, I think Pro Medicus is up there with Nanosonics Ltd (ASX: NAN) and Volpara Health Technologies Ltd (ASX: VHT) as one of the best medical technology shares on the Australian share market.

There’s no denying that its shares are expensive at 75x earnings and carry a lot of risk, but I remain confident that it can grow at a level that justifies this premium over the long-term.

As well as Pro Medicus, here are three other top mid cap shares to back in FY 2019.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited, PRO Medicus Ltd., and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!